Cardiovascular safety and scalable manufacturing for investigational new drug filing of a novel oral drug to accelerate musculoskeletal recovery in older adults - age-related loss of skeletal muscle…

Active Grant Awarded

Award ID
R44AG102216
Recipient
Awarding agency
Obligated
$2,117,233

Award facts

Assistance listing
93.866 Aging Research
Completion date 10% complete
Place of performance
Houston, TX 77021, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded Ridgeline Therapeutics, Inc. a grant with $2.117233 million obligated on September 17, 2026, under Assistance Listing 93.866, Aging Research. The award funds cardiovascular safety studies and scalable manufacturing toward an Investigational New Drug filing for a novel oral drug to accelerate musculoskeletal recovery in older adults. The project centers on small-molecule oral inhibitors of nicotinamide N-methyltransferase (NNMT). The source cites RT-002, described as Ridgeline's first-in-class NNMT inhibitor, in preclinical work: in aged mice, once-daily dosing increased muscle peak torque by 80% and doubled post-injury muscle fiber size, and in translational models, RT-002 prevented loss of muscle strength and reduced intramuscular fat infiltration.

Performance runs from the award date through an ultimate completion date of May 31, 2028, with place of performance in Houston, Texas 77021. The assistance type is a grant. The Aging Research program supports biomedical, social, and behavioral research and research training directed toward understanding the aging process and the diseases and needs of people as they age.

Description

Cardiovascular safety and scalable manufacturing for investigational new drug filing of a novel oral drug to accelerate musculoskeletal recovery in older adults - age-related loss of skeletal muscle mass, strength, and function begins by the mid-30S and accelerates rapidly after age 60, leading to a high risk for falls, trauma-related injuries, reduced mobility, and loss of independence in older ADULTS6-9. Given the rapidly expanding U.S. Senior population, musculoskeletal injuries are expected to increase substantially, imposing profound personal and financial BURDENS10. Current standards of care, primarily physical therapy and resistance exercise, are difficult to sustain in older individuals and offer only modest IM- provements in functional OUTCOMES11-12. There is a critical and urgent need for safe, effective therapeutics that directly target the biology of muscle aging and restore muscle strength and function following INJURY13. Ridgeline therapeutics is addressing this critical unmet medical need with transformative small-molecule oral drugs that inhibit nicotinamide N-methyltransferase (NNMT), a key enzyme upregulated in aging skeletal muscle to drive fundamental mechanisms of muscle WEAKNESS5, 14-15. Increased NNMT disrupts NAD+ biosynthesis, the methionine cycle, muscle stem cell (MUSC) regenerative function, and skeletal muscle METABOLISM5. Inhibiting NNMT in aged muscle exploits a unique mechanism-of-action to rejuvenate muscs and boost their regenerative capacity, resulting in rapid repair and growth of injured MUSCLES16-17 and increased muscle FUNCTION5, 18-19. In aged mice, once daily dosing with RT-002 (our first-in-class NNMT inhibitor) markedly increased muscle peak torque (a functional strength metric) by 80% and doubled post-injury muscle fiber size. In complementary translational models of age-associated muscle degeneration and weakness, RT-002 prevented loss of muscle strength, IM- proved muscle quality, and reduced intramuscular FAT infiltration. Building upon these promising results, ridgeline has completed pivotal GLP-safety/toxicity studies and assem- bled a nearly complete investigational new drug (IND) package for submission to the US food and drug ad- ministration (FDA). This direct-to-phase II sbir project addresses the three final IND requirements needed to advance RT-002 into first-in-human clinical trials. Aims 1 and 2 will extend RT-002'S negative cardiovascular (CV) findings and comprehensively confirm CV safety using advanced in vitro (HERG) and in vivo (radiotelemetry in minipig) studies. Aim 3 will complete scalable, cgmp (current good manufacturing practices) production of immediate-release oral capsules of RT-002 for clinical use. Data from these aims will finalize our IND submission, enabling initiation of phase I clinical trials. By advancing RT-002 into the clinic, we will address one of the most pressing public health needs of older adults and deliver meaningful benefits to millions of aging americans.

Quick answers

Who received award R44AG102216?

R44AG102216 was awarded to Ridgeline Therapeutics, Inc. by National Institute on Aging (National Institutes of Health) on September 17, 2026.

How much is award R44AG102216 worth?

$2,117,233 has been obligated on R44AG102216.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award